Abstract:Objecitve To investigate the effect of Kangai injection combined with CapeOX chemotherapy on the changes of phosphatidylinositol 3-kinase/serine/threonine protein kinase (PI3K/Akt) signal pathway and the quality of life in patients with advanced colon cancer. Methods A total of 66 patients with advanced colon cancer who received treatment in Chongqing Three Gorges Central Hospital from January 2016 to July 2017 were divided into CapeOX group and combined group according to the treatment plan (n=33, each).The CapeOX group was treated with CapeOX chemotherapy (oxaliplatin and capecitabine), and the combined group was treated with CapeOX chemotherapy and Kangai injection.Both groups were treated for 2 consecutive cycles (21 d as 1 cycle).The patients were followed up for 2 years.The short-term therapeutic effect and adverse reactions of the two groups were observed and statistically analyzed.The changes of serum cytokeratin 19 fragment (CYFRA21-1), carcinoembryonic antigen (CEA), PI3K/Akt signal pathway marker protein expression level and quality of life(QLQ-C30) before and after treatment were compared before and after treatment. Results There was no significant difference in the clinical effects between the study group and the control group (Z=1.061, P=0.289).The adverse reaction rate of the study group was significantly lower than that of the control group [21.21%(7/33) vs 45.45%(15/33)，χ²=4.364，P=0.037].Compared with the control group, the expression levels of PI3K and pAkt in the study group were lower after the treatment (P<0.05).Compared with the control group, the serum CYFRA21-1 and CEA levels in the study group were lower after the course of treatment, and the body, emotion, role, cognition, social function and overall health scores were higher after 2 years of follow-up (P<0.05). Conclusion The combination of CapeOX chemotherapy and Kangai injection can effectively reduce the serum CYFRA21-1 and CEA levels, inhibit the PI3K/Akt pathway, and improve the quality of life.